Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glycotex, a clinical stage biopharmaceutical company, has received a cash grant totaling $244,479 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program, for its program to develop GLYC-101 Gel investigational product for the treatment of acute and chronic wounds.
Subscribe to our email newsletter
The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.
Glycotex said that GLYC-101 is being developed to stimulate and modulate the natural cascade of wound healing activities of several cell populations.
The product candidate is a topical gel to be applied directly on the wound surface.
The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers.